MAP2K7 and prostate carcinoma: Combination mTOR/MEK inhibitor treatment resulted in decreased tumor size in MCF-7 human breast cancer xenografts [66], decreased androgen-dependent prostate cancer cell growth in vitro [68], and decreased androgen-independent prostate cancer cell growth in vitro and in vivo [69].